Cheng L, Cheville J C, Neumann R M, Bostwick D G
Department of Pathology, Indiana University School of Medicine, Indianapolis 46202, USA.
Am J Surg Pathol. 1999 Apr;23(4):443-7. doi: 10.1097/00000478-199904000-00009.
Urothelial dysplasia is the putative precursor of urothelial carcinoma in situ (CIS) and invasive urothelial carcinoma of the urinary tract. Urothelial dysplasia is frequently identified in patients with urothelial CIS and cancer. However, very little is known about the clinical presentation and natural history of urothelial dysplasia in the absence of urothelial CIS or invasive cancer. The authors studied 36 patients with isolated urothelial dysplasia at the Mayo Clinic between 1969 and 1984. None of these patients had previous or concurrent urothelial CIS or invasive cancer, and none received treatment for dysplasia. The histopathologic features of urothelial dysplasia were examined, and long-term clinical follow-up was obtained. Progression was defined as the development of urothelial CIS or carcinoma. The male-to-female ratio was 2.6:1, and the mean patient age at the time of diagnosis was 60 years (range 25-79). Urothelial dysplasia has a predilection for the posterior wall. Eleven patients had urinary irritative symptoms, 10 had hematuria, 3 had both irritative symptoms and hematuria, and 12 were found to have dysplasia incidentally. The mean follow-up was 8.2 years (range 0.1-25.5). Seven (19%) of 36 patients developed biopsy-proven progression, including 4 with CIS and 3 with invasive cancer, and 1 of them died of bladder cancer. The intervals from diagnosis to progression ranged from 6 months to 8 years (mean 2.5 years). One of the remaining 29 patients had positive cytologic results 2.5 years after the initial diagnosis of dysplasia. The authors conclude that urothelial dysplasia is a significant risk for the development of CIS and invasive urothelial carcinoma, and patients with urothelial dysplasia should be followed up closely.
尿路上皮发育异常被认为是原位尿路上皮癌(CIS)和尿路浸润性尿路上皮癌的前驱病变。尿路上皮发育异常在尿路上皮CIS和癌症患者中经常被发现。然而,对于在没有尿路上皮CIS或浸润性癌的情况下尿路上皮发育异常的临床表现和自然病程知之甚少。作者研究了1969年至1984年间梅奥诊所的36例孤立性尿路上皮发育异常患者。这些患者中没有一人有既往或同时存在的尿路上皮CIS或浸润性癌,也没有一人接受过发育异常的治疗。检查了尿路上皮发育异常的组织病理学特征,并进行了长期临床随访。进展被定义为尿路上皮CIS或癌的发生。男女比例为2.6:1,诊断时患者的平均年龄为60岁(范围25 - 79岁)。尿路上皮发育异常好发于后壁。11例患者有尿路刺激症状,10例有血尿,3例既有刺激症状又有血尿,12例是偶然发现有发育异常。平均随访时间为8.2年(范围0.1 - 25.5年)。36例患者中有7例(19%)经活检证实发生进展,包括4例CIS和3例浸润性癌,其中1例死于膀胱癌。从诊断到进展的时间间隔为6个月至8年(平均2.5年)。其余29例患者中有1例在发育异常初次诊断2.5年后细胞学检查结果呈阳性。作者得出结论,尿路上皮发育异常是发生CIS和浸润性尿路上皮癌的重大风险因素,尿路上皮发育异常患者应密切随访。